首页> 美国卫生研究院文献>PLoS Clinical Trials >Smac Mimetic SM-164 Potentiates APO2L/TRAIL- and Doxorubicin-Mediated Anticancer Activity in Human Hepatocellular Carcinoma Cells
【2h】

Smac Mimetic SM-164 Potentiates APO2L/TRAIL- and Doxorubicin-Mediated Anticancer Activity in Human Hepatocellular Carcinoma Cells

机译:Smac模拟SM-164增强人肝癌细胞中APO2L / TRAIL和阿霉素介导的抗癌活性。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundThe members of inhibitor of apoptosis proteins (IAPs) family are key negative regulators of apoptosis. Overexpression of IAPs are found in hepatocellular carcinoma (HCC), and can contribute to chemotherapy resistance and recurrence of HCC. Small-molecule Second mitochondria-derived activator of caspases (Smac) mimetics have recently emerged as novel anticancer drugs through targeting IAPs. The specific aims of this study were to 1) examine the anticancer activity of Smac mimetics as a single agent and in combination with chemotherapy in HCC cells, and 2) investigate the mechanism of anticancer action of Smac mimetics.
机译:背景凋亡蛋白抑制剂(IAPs)家族成员是凋亡的关键负调控因子。 IAP的过度表达存在于肝细胞癌(HCC)中,并且可能导致化疗耐药性和HCC复发。通过靶向IAP,小分子第二个线粒体衍生的胱天蛋白酶(Smac)模拟物激活剂已作为新型抗癌药物出现。这项研究的具体目的是:1)检查Smac模拟物作为单一药物并与HCC细胞联合化疗的抗癌活性,以及​​2)研究Smac模拟物的抗癌作用机理。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号